Third Opinion Trial Synopsis
This research study is looking at how two drugs, belantamab mafodotin and lenalidomide, can help patients with multiple myeloma. Belantamab mafodotin is a special medicine that attaches to cancer cells and kills them. Lenalidomide is a treatment that can stop cancer from growing. The researchers want to see if giving these two drugs together can help keep the cancer from coming back in patients who have already had a stem cell transplant. They want to find out if this combination of drugs can keep the disease from spreading after the initial treatment.

Trial Summary
This phase II trial investigates the effect of belantamab mafodotin and lenalidomide on minimal residual disease negative rates in patients with multiple myeloma with minimal residual disease positive after stem cell transplant. Belantamab mafodotin is a monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as B-cell maturation antigen (BCMA) receptors, and delivers mafodotin to kill them. Lenalidomide may help block the formation of growths that may become cancer, and is used as a standard of care treatment for multiple myeloma. Giving belantamab mafodotin and lenalidomide may help to maintain minimal residual disease negativity in patients with multiple myeloma.